Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology.

ABSTRACT: BACKGROUND:Incremental cost-effectiveness ratios (ICERs) are used to assess the value for money of new drugs. Many believe that ICERs for drugs that treat rare diseases are much higher than those of common drugs. Our objective was to compare the proportion of ICERs that are cost effective for rare and common cancers. METHODS:We used the Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry to identify cost-effectiveness studies of pharmaceutical interventions for cancers. Studies that assessed FDA-approved 'orphan drugs' were categorized as assessing rare cancers. The proportion of common and rare cancer drugs that were cost effective at various ICER thresholds were compared along with study characteristics. Logistic regressions were conducted to assess important predictors of co

SUBMITTER: Jayasundara K 

PROVIDER: S-EPMC5691840 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature